Congress is grappling with a busy and complex agenda before adjourning on September 27 through the election. Congress is on track to meet its deadline of October 1 to pass a government funding measure and there are several other important issues that the life sciences community is advocating for Congress to prioritize by the end of the year. Two of the key issues CBSA is keeping a close eye on include the reauthorization of the rare pediatric disease priority review voucher (PPRV) program (S. 4583 and H.R. 7384) and the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 (H.R. 1691).
- Reauthorization of the Rare Pediatric Disease Priority Review Voucher (PPRV) Program: The PPRV program is set to expire on September 30, 2024, but bipartisan and bicameral legislation, S. 4583 and…
Click here to view original postClick Here to Publish/Feature Your Company or Product News with Biotech Networks
